Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human LRP5 Antibodies:
anti-Mouse (Murine) LRP5 Antibodies:
anti-Rat (Rattus) LRP5 Antibodies:
Go to our pre-filtered search.
Human Polyclonal LRP5 Primary Antibody for EIA, WB - ABIN953209
Abramowitz, Muntner, Coco, Southern, Lotwin, Hostetter, Melamed: Serum alkaline phosphatase and phosphate and risk of mortality and hospitalization. in Clinical journal of the American Society of Nephrology : CJASN 2010
Show all 4 references for ABIN953209
Human Monoclonal LRP5 Primary Antibody for FACS, ELISA - ABIN969535
Urano, Shiraki, Usui, Sasaki, Ouchi, Inoue: A1330V variant of the low-density lipoprotein receptor-related protein 5 (LRP5) gene decreases Wnt signaling and affects the total body bone mineral density in Japanese women. in Endocrine journal 2009
Show all 2 references for ABIN969535
Human Polyclonal LRP5 Primary Antibody for WB - ABIN127323
Del Valle-Pérez, Arqués, Vinyoles, de Herreros, Duñach: Coordinated action of CK1 isoforms in canonical Wnt signaling. in Molecular and cellular biology 2011
Show all 2 references for ABIN127323
Human Polyclonal LRP5 Primary Antibody for IHC, ELISA - ABIN185410
He, Semenov, Tamai, Zeng: LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. in Development (Cambridge, England) 2004
Show all 2 references for ABIN185410
Human Monoclonal LRP5 Primary Antibody for ELISA, WB - ABIN517568
Kim, Goel, Alexander: Differentiation generates paracrine cell pairs that maintain basaloid mouse mammary tumors: proof of concept. in PLoS ONE 2011
The extracellular domains of Lrp5/6 behave as physiologically relevant inhibitors of noncanonical Wnt (show WNT2 Antibodies) signaling during Xenopus and mouse development in vivo.
Data show that in zebrafish, lrp5 also controls cell migration during early morphogenetic processes and contributes to shaping the craniofacial skeleton.
This study show LRP5 polymorphism may associate with body composition and bone mineral density in Iranian children.
Lrp5 controls glucose uptake and growth of MDA-MB-231 human breast cancer cells.
Data show that LDL receptor (show LDLR Antibodies)-related protein 5 (show CAPS Antibodies) (LRP5) gain-of-function mutations do not activate beta-catenin (show CTNNB1 Antibodies) signaling in osteoblasts.
findings suggest that rescuing LRP5/6-mediated Wnt (show WNT2 Antibodies) signaling improves neuronal cell survival and reduces tau phosphorylation, which support the hypothesis that Wnt (show WNT2 Antibodies) signaling might be an attractive therapeutic strategy for managing AD
Molecular testing identified biallelic lipoprotein receptor-related protein (show LRP1 Antibodies) 5 (show CAPS Antibodies) (LRP5) mutations (NM_002335.3:c. [889dupA]; [2827 + 1G > A]) confirming a diagnosis of osteoporosis-pseudoglioma (OPPG) syndrome.
Lrp5 binds to Frizzled, preventing Frz-regulated non-canonical Wnt (show WNT2 Antibodies) pathway activation and further non-canonical pathway-mediated tumour metastasis.
Reciprocally, a low bone mineral density-associated common LRP5 allele correlated with increased abdominal adiposity.
No mutations in LRP5 and LRP6 (show LRP6 Antibodies) could be identified
This is the first study to suggest the genetic influence of LRP5 A1330V polymorphism on bone mineral density in COPD (show ARCN1 Antibodies) patients, independent of the development of emphysema.
Although AFFs have been reported in other rare bone diseases, this is the first in a genetic condition of primary osteoblast dysfunction. The relatively low bone turnover observed, and knowledge of LRP5 function
LRP5 function in mice causes retinal hypovascularization during development as well as retinal neovascularization in adulthood with disorganized and leaky vessels.
Lrp5 is required for glucose uptake, and glucose uptake regulates the growth rate of mammary epithelial cells in culture.
These in vivo data support in vitro studies regarding the mechanism of HBM-causing mutations, and imply that HBM LRP5 receptors differ in their relative sensitivity to inhibition by SOST (show SOST Antibodies) and DKK1 (show DKK1 Antibodies).
Lrp5 A214V and G171V were partially or fully protected from the bone loss that normally results frommechanical disuse using two models, tail suspension and Botulinum toxin-induced muscle paralysis, in two different Lrp5 HBM knock-in mouse models.
In hypercholesterolemia LRP5(-/-) mice Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) pathway was shut down. An antiatherogenic role for LRP5 was demonstrated as HC LRP5(-/-) mice developed larger aortic atherosclerotic lesions than WT mice.
Report accelerated lung regeneration by platelet-rich plasma extract through Lrp5/Tie2 (show TEK Antibodies) pathway.
Data show that low density lipoprotein receptor-related protein 5 (LRP5) and the canonical Wnt (show WNT2 Antibodies) pathway down-regulation regulate the dyslipidaemic profile by promoting lipid and macrophage retention in the vessel wall.
Sclerostin (show SOST Antibodies) inhibits bone formation through Lrp5 interaction.
This gene encodes a transmembrane low-density lipoprotein receptor that binds and internalizes ligands in the process of receptor-mediated endocytosis. This protein also acts as a co-receptor with Frizzled protein family members for transducing signals by Wnt proteins and was originally cloned on the basis of its association with type 1 diabetes mellitus in humans. This protein plays a key role in skeletal homeostasis and many bone density related diseases are caused by mutations in this gene. Mutations in this gene also cause familial exudative vitreoretinopathy.
Lipoprotein Receptor Related Protein 5
, low density lipoprotein receptor-related protein 5
, low-density lipoprotein receptor-related protein 5
, low-density lipoprotein receptor-related protein 5-like
, low density lipoprotein receptor-related protein 7
, low-density lipoprotein receptor-related protein 7